BioNexus Gene Lab Price to Free Cash Flow Ratio 2019-2024 | BGLC

BioNexus Gene Lab price to free cash flow ratio from 2019 to 2024. Price to free cash flow ratio can be defined as

BioNexus Gene Lab Price to Free Cash Flow Ratio 2019-2024 | BGLC

BioNexus Gene Lab price to free cash flow ratio from 2019 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Elevance Health (ELV)$120.6B
Cencora (COR)$44.1B
ICON (ICLR)$23.6B
DiDi Global (DIDIY)$22.4B
Avantor (AVTR)$17.7B
Revvity (RVTY)$15.6B
Natera (NTRA)$15.3B
Viatris (VTRS)$13.9B
CochLear (CHEOY)$12.8B
Solventum (SOLV)$11.8B
Charles River Laboratories (CRL)$10.2B
Medpace Holdings (MEDP)$10.1B
Sonic Healthcare (SKHHY)$9.1B
Doximity (DOCS)$7.9B
HealthEquity (HQY)$6.9B
Bausch + Lomb (BLCO)$6.7B
PACS (PACS)$6B
Organon (OGN)$4.9B
Life Times (LTH)$4.9B
Sotera Health (SHC)$4.7B
Surgery Partners (SGRY)$4.1B
Concentras Parent (CON)$2.9B
Ardent Health Partners (ARDT)$2.7B
GoodRx Holdings (GDRX)$2.5B
BrightSpring Health Services (BTSG)$2.5B
Alignment Healthcare (ALHC)$2.1B
Premier (PINC)$2B
Ryman Healthcare (RYHTY)$2B
AMN Healthcare Services Inc (AMN)$1.6B
CareDx (CDNA)$1.6B